Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
PerkinElmer (NYSE: PKI) reported strong Q1 2021 results with GAAP earnings per share of $3.37, up from $0.30 in Q1 2020, and revenues of $1.308 billion, a significant increase from $652 million year-over-year. The operating income was $468 million, reflecting a profit margin of 35.8%. Diagnostics revenue soared 236% to $853 million. The company raised its 2021 revenue guidance to $4.37 billion, and EPS forecast to $7.77 for the year.
The Board of Directors of PerkinElmer declared a regular quarterly dividend of $0.07 per share on April 29, 2021. This dividend is set to be paid on August 6, 2021, to shareholders of record as of July 16, 2021.
PerkinElmer reported revenue of approximately $3.8 billion in 2020, boasting a workforce of around 14,000 employees across 190 countries. The company is a component of the S&P 500 Index.
Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced that its T-SPOT® Discovery SARS-CoV-2 kit will be used in the DIRECT study, which investigates immune responses to COVID-19 in ethnic minority healthcare workers. The study, funded by the National Core Studies group, aims to assess whether vaccination induces a T cell response, potentially revealing disparities in immune responses among different groups. The T-SPOT technology offers advantages over conventional antibody testing, providing critical insights into immunity and potential protection against infection.
Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced its T-SPOT® Discovery SARS-CoV-2 kit will be utilized in the UK Com-COV trial. This trial, led by the Oxford Vaccine Group, investigates immune responses from different COVID-19 vaccine combinations. Funded by the UK Vaccine Task Force, the trial's first phase has enrolled 830 participants and is expanding to include an additional 1,050. The goal is to evaluate how mixed vaccination schedules enhance immune responses, potentially providing longer-lasting protection against evolving virus variants.
PerkinElmer (NYSE: PKI), a global leader in health innovation, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 9:30 a.m. ET. CEO Prahlad Singh will update on the company's strategic priorities. A live audio webcast will be available on the Investors section of their website, with a replay accessible for 90 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and operates in 190 countries with over 14,000 employees.
PerkinElmer (NYSE: PKI) anticipates a remarkable 98% growth in reported revenue and 90% in organic revenue for Q1 ending April 4, 2021. This performance is attributed to strong core demand, with 10% organic growth in non-COVID-19 segments and approximately $535 million from COVID-19 solutions. Financial results will be disclosed on May 4, 2021, alongside a conference call led by CEO Prahlad Singh and CFO Jamey Mock. Additionally, Steve Willoughby will assume the role of VP of Investor Relations starting May 5, 2021.
PerkinElmer's Horizon Discovery has expanded its gene editing portfolio with new CRISPR modulation (CRISPRmod) reagents, enabling gene repression at the transcriptional level. This includes synthetic single guide RNAs for CRISPR interference and a novel dCas9-SALL1-SDS3 repressor, enhancing gene modulation performance. These advancements aim to aid researchers in understanding disease pathways and exploring therapeutic options. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and serves customers globally.
PerkinElmer, Inc. (NYSE: PKI) has finalized its acquisition of Oxford Immunotec Global PLC, recognized for its T-SPOT®.TB tuberculosis test. The acquisition aims to enhance PerkinElmer's diagnostic capabilities, leveraging automation and commercial access to expand market reach for tuberculosis testing. Oxford Immunotec reported revenues of $73.74 million in 2019. This strategic move aligns with PerkinElmer's mission to innovate for better health outcomes worldwide.
PerkinElmer (NYSE: PKI) has introduced two new Research Use Only (RUO) solutions: PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit. These assays allow laboratories to analyze genomic mutations in SARS-CoV-2 variants from previously positive samples. The PKamp assay detects mutations related to dominant variants like B.1.1.7 and B.1.351, enhancing COVID-19 testing capabilities. PerkinElmer continues to innovate amidst evolving public health challenges.
PerkinElmer (NYSE: PKI) has priced a $400 million offering of 2.550% Senior Notes due 2031 and 3.625% Senior Notes due 2051. The offering, expected to close on March 8, 2021, aims to utilize approximately $561 million of net proceeds to repay debt related to its acquisition of Oxford Immunotec Global PLC and to refinance existing senior notes. This strategic move aligns with the company's focus on innovation and maintaining a healthy financial position.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
